Approved to treat adults with pulmonary arterial hypertension.
Tradename Ultravi.
Indicated for the treatment of pulmonary arterial hypertension, to delay disease progression and reduce the risk of hospitalization for PAH.
Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by dyspnea, fatigue, syncope, edema, cyanosis and heart palpitations.
Belongs to a class of drugs called oral prostacyclin receptor agonists, and acts by relaxing muscles in the walls of blood vessels to dilate blood vessels and decrease elevated pressure in the vessels supplying blood to the lungs.
Effective in reducing hospitalization for PAH and reducing the risks of disease progression compared to placebo.
Common side effects include:headache, diarrhea, jaw pain, nausea, muscle pain,vomiting, pain in an extremity, and flushing.